|TEV||-2||TEV/EBIT||0||TTM 2019-06-30, in MM, except price, ratios|
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported) May 21, 2019
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction |
|(Commission File |
|(Address of Principal Executive Offices)||(Zip Code)|
|(Registrant’s telephone number, including area code)|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).
|Emerging growth company ☒|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act: None
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 15, 2019, Dr. Ryan Thomas, who has served the company as its President and is a member of the Board of Directors of the company, has resigned his position as President, effective immediately. Dr. Thomas will maintain his role as general counsel to the company, as well as serving on the Board.
On May 15, 2019, Mr. Emil Malak, who currently serves the company as its Chief Executive Office and is a member of the Board of Directors of the company, has assumed the role of President, effective immediately. Mr. Malak will also maintain his roles as CEO and as a member of the Board.
Information required by 17 CFR 229.401 for both Dr. Thomas and Mr. Malak is available in the company’s most recent 10K report.
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|DATED: May 21, 2019||By:||/s/ Emil Malak|
|Chief Executive Officer|
|DATED: May 21, 2019||By:||/s/ D. Barry Lee|
|D. Barry Lee|
|Chief Financial Officer|